We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury

By LabMedica International staff writers
Posted on 08 Jan 2025
Print article
Image: Researchers have identified six biomarkers of kidney injury (Photo courtesy of 123RF)
Image: Researchers have identified six biomarkers of kidney injury (Photo courtesy of 123RF)

Drug-induced kidney injury, also known as nephrotoxicity, is a frequent complication in clinical medicine, occurring when drugs damage the kidneys. This can result from various medications, including anti-inflammatory, antibacterial, antiretroviral, and chemotherapeutic drugs, and may lead to the discontinuation or restriction of treatment. Current biomarkers are often too slow to detect early signs of kidney damage. Researchers have now identified six new biomarkers that could enable quicker and more sensitive detection of kidney injury, paving the way for safer drug development and better patient outcomes. Early detection of kidney damage could allow clinicians to intervene sooner, potentially reducing long-term harm and improving patient health in diverse medical settings.

These newly discovered biomarkers, identified by researchers at Boston Medical Center (Boston, MA, USA), may offer a more sensitive approach compared to current standards for monitoring kidney health, leading to more tolerable treatment options. The research team analyzed urinary protein biomarkers in both healthy volunteers and patients being treated for mesothelioma with a chemotherapy drug known to be toxic to the kidneys. The six biomarkers they identified are primarily produced by the kidneys in response to injury or inflammation, enabling faster detection of kidney injury than traditional blood tests like serum creatinine, which can take days to show abnormal levels. The research team now aims to explore whether these biomarkers can be applied more broadly for monitoring kidney health in clinical trials.

"These biomarkers, which can be measured in the urine, could help clinicians detect kidney damage within 24 hours of injury, enabling more timely monitoring during drug development and better treatment of patients who are at risk in clinical settings," said Sushrut Waikar, MD, MPH, first author on the paper published in Clinical Pharmacology & Therapeutics. "These biomarkers have the potential to make a real difference in how we monitor kidney health and manage patients at risk for kidney damage. We are hopeful that these findings will contribute to better strategies for preserving kidney function and improving patient care, as well as advancing safer drug development."

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.